Excellence is just the beginning.


French German Italian Portuguese Russian

Treatment Study for Patients with Localized Central Nervous System Germ Cell Tumors

Clinical Trial Title: 
Phase 2 trial of response-based radiation therapy for patients with localized central nervous system germ cell tumors (CNS GCT).
Clinical Trial Protocol ID: 
Clinical Trial Investigator Name: 
Mary Lou Schmidt, MD
Clinical Trial Protocol Description: 

To determine, as measured by the 3-year progression free survival rate and patterns of failure, whether simplified chemotherapy followed by dose-reduced radiation therapy is effective for treating children and young adults (ages 3 to < 21 years) with localized  primary central nervous system (CNS) germinoma who present with serum and/or CSF human chorionic gonadotropin-beta (hCGI3) < 50miU/ml.

Clinical Trial Eligibility Criteria: 

In order to participate you must meet the following criteria:

  • Are between 3 and 21 years of age at the time of study enrollment.
  • Have been newly diagnosed with localized primary CNS NGGCT (Stratum  1) or localized primary CNS germinoma (Stratum 2). Germ cell tumors located in the suprasellar  pineal, bifocal (pineal + suprasellar) and ventricles are eligible. Tumors present  in the above mentioned locations and with unifocal parenchymal extension are eligible.

This is a partial list of elgibility requirements.

Clinical Trial Area: 
Blood Disorders and Hematologic Cancers
Contact Phone: 
(312) 355-0741
Contact Name: 
Nitin Sane